Shares of Catasys Inc. (NASDAQ:CATS) have been assigned an average broker rating score of 1.00 (Strong Buy) from the one brokers that cover the stock, Zacks Investment Research reports. One research analyst has rated the stock with a strong buy recommendation.

Brokerages have set a 1-year consensus price target of $12.00 for the company, according to Zacks. Zacks has also assigned Catasys an industry rank of 35 out of 265 based on the ratings given to related companies.

Separately, Zacks Investment Research upgraded Catasys from a “sell” rating to a “hold” rating in a research note on Monday.

TRADEMARK VIOLATION WARNING: “Zacks: Catasys Inc. (NASDAQ:CATS) Given $12.00 Average Price Target by Brokerages” was originally published by American Banking News and is owned by of American Banking News. If you are accessing this article on another domain, it was stolen and republished in violation of US & international copyright law. The correct version of this article can be viewed at https://www.americanbankingnews.com/2017/08/08/zacks-catasys-inc-nasdaqcats-given-12-00-average-price-target-by-brokerages.html.

Catasys (NASDAQ:CATS) opened at 4.61 on Tuesday. The company’s market cap is $73.18 million. The stock has a 50 day moving average price of $4.43 and a 200-day moving average price of $6.56. Catasys has a 1-year low of $3.56 and a 1-year high of $14.00.

A hedge fund recently bought a new stake in Catasys stock. Perkins Capital Management Inc. bought a new stake in Catasys Inc. (NASDAQ:CATS) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 24,700 shares of the company’s stock, valued at approximately $113,000. Perkins Capital Management Inc. owned approximately 0.16% of Catasys as of its most recent filing with the SEC. 2.19% of the stock is owned by institutional investors and hedge funds.

About Catasys

Catasys, Inc provides data analytics based specialized behavioral health management and integrated treatment services to health plans and other third party payors. It offers OnTrak solution to improve treatment outcomes and lower the utilization of medical and behavioral health plan services. The company’s OnTrak solution includes medical and psychosocial interventions; and a proprietary Web based clinical information platform and database, psychosocial programs, and integrated care coaching services.

Get a free copy of the Zacks research report on Catasys (CATS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Catasys Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catasys Inc. and related companies with MarketBeat.com's FREE daily email newsletter.